Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

LPS-Pro Lipopolysaccharide Lipid A Profiling to Guide Microbiome-Supported Immunotherapy in Melanoma

Coordinator
Universita Degli Studi Di Napoli Federico Ii, Italy
Runs
1 January 2027 to 30 June 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101334827

What the project is doing

In the project's own words, from its summary on CORDIS.

Understanding how gut microbiota shapes host physiology is central to biomedicine. Yet current microbiome studies largely infer function from genetic signatures rather than directly measuring biochemical outputs. This limitation becomes critical in interventional settings such as faecal microbiota transplantation (FMT) in oncology, where donor-to-recipient transfer can alter immune tone in ways not captured by taxonomy alone.

Among key microbial immune modulators are lipopolysaccharides (LPS) from Gram-negative bacteria. The ERC StG DEBUGGING-LPS demonstrated that gut microbiota-derived LPS are not chemically equivalent and that specific LPS lipid A structural features dictate pro- or non-inflammatory output. However, this molecular information is not resolved in current microbiome monitoring approaches, limiting interpretation of microbiome-based interventions like FMT.Building on our validated lipid A profiling workflow and preliminary data in melanoma patients, LPS-Pro will prototype and validate a multiplexed platform for longitudinal lipid A profiling in faecal samples.

By enabling chemistry-resolved and decision-oriented monitoring of Gram-negative inflammatory signals, LPS-Pro will contribute to more informed donor selection, more efficient therapy monitoring, and improved risk stratification in melanoma. To strengthen our science case (A), we will convert the validated lipid A extraction and MALDI-TOF workflow into a multiplexed format; implement internal references and decision criteria to ensure robustness and reproducibility; and use functional immune assays to validate the biological relevance of the lipid A-based readout.

To prepare for future use (B), we will consolidate the intellectual property position; analyse the microbiome diagnostics and oncology market; and define the most viable commercialisation route, including licensing, service-based deployment or spin-off creation.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di Napoli Federico IiNapoliItalyCoordinator
Meta Group SRLRomaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI